These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 25903738

  • 1. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
    Berger B, Baumgartner A, Rauer S, Mader I, Luetzen N, Farenkopf U, Stich O.
    J Neuroimmunol; 2015 May 15; 282():118-22. PubMed ID: 25903738
    [Abstract] [Full Text] [Related]

  • 2. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 15; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 4. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 5. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T.
    Arch Neurol; 2012 Feb 04; 69(2):262-4. PubMed ID: 22332194
    [Abstract] [Full Text] [Related]

  • 6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Feb 04; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 7. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 8. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 04; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Jun 04; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 10. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 04; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 11. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
    Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.
    Clin Neurol Neurosurg; 2014 Apr 04; 119():17-20. PubMed ID: 24635919
    [Abstract] [Full Text] [Related]

  • 12. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013 Apr 04; 129(5):548-9. PubMed ID: 23520898
    [Abstract] [Full Text] [Related]

  • 13. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar 04; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 14. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T, MSBase Study Group.
    JAMA Neurol; 2015 Apr 04; 72(4):405-13. PubMed ID: 25665031
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 04; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 16. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P.
    Mult Scler; 2012 Nov 04; 18(11):1640-3. PubMed ID: 23100526
    [Abstract] [Full Text] [Related]

  • 17. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep 04; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

  • 18. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.
    Curr Med Res Opin; 2012 May 04; 28(5):767-80. PubMed ID: 22462530
    [Abstract] [Full Text] [Related]

  • 19. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N, Kim E.
    Clin Ther; 2012 Jul 20; 34(7):1583-90. PubMed ID: 22749258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.